| BURU 0.2231 0.86% | PLUG 3.81 34.63% | ASNS 0.6247 68.84% | DFLI 1.89 76.64% | CHR 0.1609 22.64% | OPEN 8.11 1.25% | SOXS 4.69 1.96% | BNAI 0.6015 69.44% | TSLL 19.63 -2.92% | RKT 17.8 -3.10% | LAC 9.04 31.78% | SNAP 8.54 3.89% | RGTI 40.06 13.16% | NVDA 187.62 -0.67% | TSLA 429.83 -1.42% | CAN 1.31 -0.76% | INTC 36.83 -1.26% | SQQQ 15.05 1.42% | DNN 2.8 1.08% | QUBT 24.62 23.22% | PSLV 16.13 2.35% | GPUS 0.54 11.57% | ACHR 11.57 13.65% | PLTR 173.07 -7.47% | RR 6.18 19.77% | F 12.67 3.68% | QBTS 32.7 11.95% | BBAI 7.19 -1.10% | TLRY 1.62 0.62% | TSLQ 8.51 2.78% | IBIT 69.81 1.51% | SOFI 25.24 -2.81% | AAL 11.58 1.31% | IONZ 3.4 -11.92% | QS 15.92 11.33% | SOUN 17.85 0.06% | DVLT 1.34 -12.42% | ONDS 9.91 7.60% | PFE 27.37 1.07% | SOXL 38.23 -2.18% | CIFR 14.7 6.44% | SPY 669.21 0.00% | HIVE 4.45 2.06% | CJET 0.169 -0.59% | BITF 3.01 2.73% | BBD 3.17 0.11% | SHOT 0.3702 31.74% | ANRO 6.89 56.24% | NIO 7.7 -2.41% | MARA 18.82 0.16%
Article image

Comparative Analysis of Avenue Therapeutics, Revelation Biosciences, and Ensysce Biosciences

Avenue Therapeutics, Inc. (NASDAQ:ATXI) is a specialty pharmaceutical company focused on developing and commercializing therapies for the treatment of pain. Currently, ATXI's stock price is $0.36, with a target price of $0.20. This target price is 45.13% lower than the current market price, reflecting a negative outlook from investment analysts.

In contrast, Revelation Biosciences, Inc. (REVB) has a current stock price of $2.51 and a DCF valuation of $3.79. This results in a price percentage difference of 50.98%, indicating a potential for growth. REVB's market cap stands at $5,094,795, but it has a negative EPS of -246.21 and a PE ratio of -0.25, suggesting financial challenges despite the positive price outlook.

Ensysce Biosciences, Inc. (ENSC) has a stock price of $2.36, with a DCF valuation of $1.83, leading to a price percentage difference of -22.36%. ENSC's market cap is $5,594,852, and it has an EPS of 110.31. ENSC offers a dividend yield of 20.40%, which may attract income-focused investors.

Published on: July 14, 2025